Suppr超能文献

临床试验中的生物统计学:第2部分。确定临床试验的样本量。

Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.

作者信息

Ellenberg S S

机构信息

Division of AIDS, National Institute of Allergy and Infectious Diseases.

出版信息

Oncology (Williston Park). 1989 Aug;3(8):39-46; discussion 48, 51.

PMID:2519197
Abstract

The appropriate sample size for a clinical trial depends on the objectives of the trial. For Phase II trials, the recommended sample size is generally in the neighborhood of 25-40 patients, regardless of the choice of design. Sample sizes for Phase III trials are much more variable, ranging from less than a hundred to thousands of patients. The methodology of sample size determination for Phase III trials depends on the type of endpoint that is to be the primary focus of analysis. Tables of sample sizes for a variety of situations are presented. Use of sequential designs may reduce the required sample size by permitting early termination of trials whose results become definitive prior to completion of patient entry.

摘要

临床试验的合适样本量取决于试验的目标。对于II期试验,无论设计如何选择,推荐的样本量一般在25至40名患者左右。III期试验的样本量变化大得多,从不到一百名患者到数千名患者不等。III期试验样本量确定的方法取决于作为主要分析重点的终点类型。文中给出了各种情况下的样本量表格。采用序贯设计可以在患者入组完成前,当试验结果明确时提前终止试验,从而可能减少所需的样本量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验